New eczema pill aims to calm angry skin

NCT ID NCT07344051

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental capsule called QLS12010 in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo over 16 weeks. Participants must have had eczema for at least one year and meet specific severity scores. The trial is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.